The pharmacokinetics of cefoperazone, a new fi-lactam antibiotic, were studied in normal volunteers and compared with the pharmacokinetics of cefamandole. After a 30-min infusion of 2 g of cefoperazone, the mean serum level was 256 ,ug/ ml; at 4 h, the serum level was 20 yg/ml, and at 12 h, the level was 1.25 ytg/ml, compared with levels of cefamandole of 188 yg/ml at the end of infusion, 1.8 jtg/ ml at 4 h, and none detected thereafter. The mean half-life of cefoperazone was 1.6 h, compared with 0.7 h for cefamandole. The area under the curve was 356 jtg/ml per h for cefoperazone, which was three times that for cefamandole. The apparent volume of distribution for cefoperazone was 9.9 liters/1.73 m2 compared with 12.5 liters/1.73 m2 for cefamandole. Serum clearance of cefoperazone was 85 ml/min, and renal clearance was 25 ml/min, compared with a serum clearance of 224 ml/min and a renal clearance of 213 ml/min for cefamandole. Urine levels exceeded 25 fig/ml in the first 8 h after injection. Renal recovery of cefoperazone was only 29%.
There has been a constant search for newer /1-lactam antibiotics which are resistant to inactivation by the 13-lactamases of Enterobacteriaceae and Pseudomonas species. Cefoperazone is a piperazine cephalosporin which combines many of the properties of cefamandole and piperacillin in its in vitro spectrum with greater activity than either agent (7) . The purpose of this study was to compare the pharmacokinetics of cefoperazone and cefamandole after a single intravenous dose (2 g ) to determine whether the serum levels achieved would allow a two-or three-times-per-day dosing program.
MATERIALS AND METHODS
Cefoperazone and cefamandole were supplied by Pfizer Pharmaceuticals and Lilly Research Laboratories, respectively. The antibiotics were reconstituted in sterile water for administration. Seven normal male subjects between the ages of 24 and 35 were used in this study. All subjects were judged healthy on the basis of normal physical examinations, complete blood counts, urinalysis, and blood chemical studies. Informed, written consent in accordance with the institutional guidelines was obtained from each subject.
The mean age of the subjects was 28 years (range, 24 to 35); the mean weight was 72.5 kg (range, 68 to 86); and the mean body surface area was 1.88 m2 (range, 1.29 to 2.1).
Each of the seven subjects received either 2 g of cefoperazone or 2 g of cefamandole infused intravenously through a small-bore needle over a 30-min period. The When the blood samples had clotted, they were immediately centrifuged, and the serum was decanted. Duplicate samples for each time point were stored at -20°C. Standards of lithium cefamandole and sodium cefoperazone were prepared in pooled human serum obtained from the same subjects before beginning the study and which had been shown to lack antibacterial activity. Urine samples were also immediately frozen and subsequently diluted in 0.05 M potassium phosphate buffer, pH 7.0, and assayed against antibiotic standards prepared in the same buffer. Both cefamandole and cefoperazone are stable under these conditions (7, 8) . Furthermore, samples of cefoperazone and cefamandole at concentrations of 100 and 1 jug/ml were prepared in the serum on the day of infusion, frozen, and assayed when all the samples were assayed.
Cefoperazone and cefamandole were assayed by the agar well dfffusion technique, using antibiotic medium no. 2 (Difco Laboratories) as previously described (6, 7) . Cefoperazone was assayed with an Escherichia coli strain from our collection, and cefamandole was measured in a similar fashion with Staphylococcus aureus ATCC 3472. All samples were tested in quadruplicate. 80 ,Lg/ml. Samples which gave results outside the linear part of the curve were diluted in pooled serum which lacked antibacterial activity and reassayed with samples which had not been thawed. Calculations. Pharmacokinetic parameters were determined with standard methodology (3) . Regression lines were determined statistically by the method of least squares. A two-compartment analysis was used (3), and the effect of infusion was considered (5). 
RESULTS
The mean serum concentration of cefoperazone after a 30-min intravenous infusion of 2 g is shown in Fig. 1 . The mean serum level at the end of infusion was 256 ,ug/ml, with a range of 200 to 326 ,ig/ml. At 1 h, the mean serum level was 108 ,ug/ml; at 4 h, the mean level was 20 ,ug/ ml; at 6 h, the mean level was 11 ,ig/ml; at 8 h, the mean level was 4.2 ug/ml; and at 12 h, the mean level was 0.25 ,ug/ml. We did not detect any drug at 24 h. The mean half-life for cefoperazone was 1.6 h. The apparent volume of distribution was 9.9 liters/1.73 M2. Both the serum and renal clearances of cefoperazone were low, with a serum clearance of 85 ml/min and a renal clearance of 25 ml/min. Urine levels of cefoper- (Fig. 2) .
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twice that of cefamandole and only 15% less than that of cefazolin (1, 6) . Although the serum and renal clearances of cefoperazone are similar to +1 +1 r those of cefazolin, urinary recovery is only 25^, compared with a reported recovery of 70 to 90'/i E q >_ X for cefazolin and other cephalosporins (6) . The +1 results of this study are in close agreement with those of three studies published after the man-= X = E @ > uscript was submitted for publication (1, 4, 8) . (8) showed that cefoperazone was not metabolized and that high concentrations could be found in the bile. In ill patients with biliary obstruction, we have recovered the majority of the drug in the urine (95%; manuscript in preparation).
